Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Conditions: Recurrent B Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory B-Cell Non-Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma Interventions: Biological: Interferon Beta-1A; Procedure: X-Ray Imaging; Procedure: Echocardiography; Procedure: Multigated Acquisition Scan; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Lumbar Puncture; Procedure: Bone Marrow Aspira tion; Procedure: Bone Marrow Biopsy; Procedure: Biospecimen Collection; Procedure: Biopsy Sponsors: Fred Hutchinson Cancer Center; Faron Pharmaceuticals Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avonex | Cancer & Oncology | Leukemia | Lymphoma | Mergers and Aquisitions | PET Scan | Rebif | Research | Toxicology